Xinghong Tang

Numerous randomized, double-blind, placebo-controlled trials have unequivocally demonstrated the efficacy of Paliperidone in addressing the complexities of schizophrenia. Despite these findings, the variability in individual responses to Paliperidone remains a significant consideration. This investigation seeks to delineate the influence of clinico-demographic and early-response features on Paliperidone drug response, serving as a fundamental pillar in the establishment of precision psychiatry.

We previously applied random effects latent class analysis to clinical samples to identify MDD subtypes and have extended the method to schizophrenia.